| US 7,521,193 B2 | ||
| Human diabetes-mediating proteins | ||
| Peter Mose Larsen, Odense (Denmark); Stephen J. Fey, Aarhus (Denmark); Jørn Nerup, Holte (Denmark); and Allan E. Karlsen, Allerød (Denmark) | ||
| Assigned to Pride Proteomics A/S, Odense M (Denmark) | ||
| Appl. No. 10/508,255 PCT Filed Mar. 20, 2003, PCT No. PCT/DK03/00190 § 371(c)(1), (2), (4) Date Sep. 30, 2005, PCT Pub. No. WO03/078456, PCT Pub. Date Sep. 25, 2003. |
||
| Claims priority of application No. 2002 00431 (DK), filed on Mar. 20, 2002. | ||
| Prior Publication US 2006/0073134 A1, Apr. 06, 2006 | ||
| Int. Cl. G01N 33/53 (2006.01); C07K 14/00 (2006.01) | ||
| U.S. Cl. 435—7.1 [530/350] | 4 Claims |
| 1. A method for diagnosing diabetes in a mammal, the method comprising determining in a pancreas sample the level of expression
of at least one marker protein selected from the group consisting of:
a) P05451 (known as islet cell regeneration factor; lithostathine 1 alpha, pancreatic stone protein; and pancreatic thread
protein);
b) P 19971 (known as thymidine phosphorylase; platelet derived endothelial cell growth factor; and gliostatin);
c) P30740 (known as leukocyte elastase inhibitor); and
d) P80188 (known as alpha 2 microglobulin related subunit of MMP and lipocalin-2),
wherein increased expression of a), b), c) and/or d) indicates that the mammal has diabetes.
|